Boston Scientific (BSX) Stock Forecast & Price Target

$90.46 +0.35 (+0.39%)

(As of 04:10 PM ET)

Boston Scientific - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 23 Analyst Ratings

Sell
0

Hold
3

Buy
20

Based on 23 Wall Street analysts who have issued ratings for Boston Scientific in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 23 analysts, 3 have given a hold rating, 19 have given a buy rating, and 1 has given a strong buy rating for BSX.

Consensus Price Target

$95.52
5.60% Upside

According to the 23 analysts' twelve-month price targets for Boston Scientific, the average price target is $95.52. The highest price target for BSX is $110.00, while the lowest price target for BSX is $68.00. The average price target represents a forecasted upside of 5.60% from the current price of $90.46.

Get the Latest News and Ratings for BSX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Boston Scientific and its competitors.

BSX Analyst Ratings Over Time

Type	Current Forecast 12/17/23 to 12/16/24	1 Month Ago 11/17/23 to 11/16/24	3 Months Ago 9/18/23 to 9/17/24	1 Year Ago 12/17/22 to 12/17/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	19 Buy rating(s)	19 Buy rating(s)	18 Buy rating(s)	16 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$95.52	$93.39	$85.38	$60.95
Forecasted Upside	5.60% Upside	7.36% Upside	3.47% Upside	9.22% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

Buffett's Oil Bet + This 22% Dividend Play (Ad)

Warren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occidental and Chevron) pay modest dividends of 1.47% and 4%, we've found a way for regular investors to potentially earn a much bigger income stream from the energy boom.

Click here to get the full story >>

BSX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BSX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Boston Scientific Stock vs. The Competition

Type	Boston Scientific	Medical Companies	S&P 500
Consensus Rating Score	2.91	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	3.75% Upside	30,075.70% Upside	10.55% Upside
News Sentiment Rating	Positive News See Recent BSX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/16/2024	JPMorgan Chase & Co. 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$100.00 ➝ $110.00	+21.21%
12/12/2024	TD Cowen 5 of 5 stars		Boost Target	Buy ➝ Buy	$100.00 ➝ $110.00	+21.11%
12/11/2024	Citigroup 3 of 5 stars		Boost Target	Buy ➝ Buy	$98.00 ➝ $107.00	+18.27%
12/11/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$98.00 ➝ $100.00	+10.42%
12/9/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$98.00 ➝ $101.00	+12.92%
11/27/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Matson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold
Get the Latest News and Ratings for BSX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter.
10/24/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$92.00 ➝ $100.00	+16.41%
10/24/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$92.00 ➝ $100.00	+16.69%
10/24/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$95.00 ➝ $98.00	+13.49%
10/24/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$100.00 ➝ $110.00	+25.79%
10/22/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$90.00 ➝ $100.00	+13.39%
10/18/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$85.00 ➝ $100.00	+14.17%
10/14/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$84.00 ➝ $93.00	+6.72%
10/14/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$90.00 ➝ $100.00	+14.68%
10/1/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$82.00 ➝ $90.00	+7.80%
9/4/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Strong-Buy ➝ Strong-Buy	$91.00 ➝ $94.00	+15.85%
8/22/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$78.00 ➝ $86.00	+8.08%
7/25/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$73.00 ➝ $78.00	+2.63%
7/25/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$90.00 ➝ $91.00	+17.03%
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$90.00	+20.05%
5/28/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$80.00 ➝ $95.00	+26.51%
4/25/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$74.00 ➝ $90.00	+22.97%
2/1/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform ➝ Market Perform	$58.00 ➝ $68.00	+5.44%
7/6/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$58.00 ➝ $62.00	+16.43%
6/30/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Initiates
6/30/2023	CL King Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$64.00	+20.10%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 04:43 PM ET.

Should I Buy Boston Scientific Stock? BSX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, December 15, 2024. Please send any questions or comments about these Boston Scientific pros and cons to contact@marketbeat.com.

Boston Scientific
Bull Case

Here are some ways that investors could benefit from investing in Boston Scientific Co.:

Boston Scientific Co. has shown strong financial performance, with a revenue increase of 19.3% compared to the same quarter last year, indicating robust growth in its medical device market.
The company has a solid return on equity of 17.23%, which suggests effective management and profitability relative to shareholder equity, making it an attractive option for investors seeking returns.
Recent analyst upgrades have boosted the target price for Boston Scientific Co. to as high as $110.00, reflecting positive market sentiment and potential for stock appreciation.
As of the latest trading session, the stock price is $90.07, which may present a buying opportunity for investors looking to enter at a favorable price point.
Institutional investors hold a significant 89.07% of the company's stock, indicating strong confidence from large financial entities in Boston Scientific Co.'s future performance.

Boston Scientific
Bear Case

Investors should be bearish about investing in Boston Scientific Co. for these reasons:

Despite positive growth, the stock has experienced insider selling, with executives selling over 328,157 shares worth nearly $28 million in the last ninety days, which could signal a lack of confidence in the company's short-term prospects.
Recent downgrades from analysts, including a shift from a "buy" to a "hold" rating, may indicate potential challenges ahead for the company's stock performance.
The company's debt-to-equity ratio stands at 0.44, which, while manageable, suggests that Boston Scientific Co. is somewhat reliant on debt financing, potentially increasing financial risk.
With a current ratio of 1.48, while above 1 indicates liquidity, it also suggests that the company may not have a significant buffer to cover short-term liabilities, which could be a concern in volatile market conditions.
Market competition in the medical device sector is intense, and any failure to innovate or maintain market share could adversely affect Boston Scientific Co.'s growth trajectory.

BSX Forecast - Frequently Asked Questions

: According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for Boston Scientific is $95.52, with a high forecast of $110.00 and a low forecast of $68.00.
: 23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last twelve months. There are currently 3 hold ratings, 19 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BSX shares.
: According to analysts, Boston Scientific's stock has a predicted upside of 5.60% based on their 12-month stock forecasts.
: Over the previous 90 days, Boston Scientific's stock had 1 downgrade by analysts.
: Boston Scientific has been rated by research analysts at Bank of America, BTIG Research, Canaccord Genuity Group, Citigroup, Evercore ISI, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Royal Bank of Canada, Sanford C. Bernstein, Stifel Nicolaus, TD Cowen, Truist Financial, and Wells Fargo & Company in the past 90 days.
: Analysts like Boston Scientific more than other "medical" companies. The consensus rating score for Boston Scientific is 2.91 while the average consensus rating score for "medical" companies is 2.81. Learn more on how BSX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)

The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.

👉[Click here to get your FREE report delivered instantly!]

This page (NYSE:BSX) was last updated on 12/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Boston Scientific (BSX) Stock Forecast & Price Target